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Introduction. Advances techniques are indicated for the treatment of acoustic neuromas. We use Linear Accelerator (Linac) Precise
with Dynamics Arcs Radiotherapy (DART) with Micromultiláminas and recently an optimizacion of treatments is added with the
Image Guided Radiotherapy (IGRT) and Hexapod table.
Objectives. Report the value of stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (RTEF) on local control
of acoustic neuromas.
Method. From April 2005 to January 2013, 59 patients were treated with acoustic neuromas. 57 cases were unilateral and two
cases were patients with neuroﬁbromatosis type II. 50 patients received SRS with doses of 12 Gy (excluding 2 patients with 13 Gy
and 14 Gy) and 9 patients have received RTEF due to tumor size, performance status or refuse the ﬁxed frame. The prescription
doses were 54 Gy 1.8 Gy per fraction, 50 Gy 2 Gy per fraction and other with altered fractionation. The tumor volume ranged
from 0.2 and 29.6 cc. (median 2.9 cc). Hearing loss, tinnitus and dizziness are the inicial symthoms. Treatment is indicated in
asymptomatic patients when tumor size is over 1 cm.
Results. Median follow-up is 23 months (1-94). The same tumor size remain in 24 neurinomas (40%), in 26 (44%) showed a decrease
in size. Tumor size increased in 8 mm in the patients with neuroﬁbromatosis. 8 patients did not have MRI even after 6 months
of treatment to assess it. 5 patients showed progression in hearing loss while another 8 showed an improvement. One patient
showed progression in dizziness and 13 a clear improvement. 4 patients had a temporary and slight facial hypoesthesia and 2
patients have incomplete facial paralysis two months after treatment, both in intracanalicular tumors.
Conclusions. SRS and RTEF with AL and DART with Micromultiláminas achieves low toxicity with an excellent local control and
quality of life.
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Purpose. In this paper,weused the intra frationmotion review technique (IMR, Varianmedical system),which allows simultaneous
kV/MV utilization to analyse motion management during gated RapidArc treatment.
Materials and Methods. Eight liver cancer patientswith implantedﬁducialmarkerswere treatedusing the gatedRapidArc technique
with a Varian Novalis Truebeam linear accelerator. The ﬁducial markers were implanted inside or close to the tumor target before
treatment simulation. For patient simulation, three to four 4D computed tomography (CT) scans were acquired using Real time
Position Management (RPM) system to study the reproducibility of liver motion. The cine 4D CT images were separated into
10 phases CT series based on respiratory motion information. A Maximum Intensity Projection (MIP) and an Average Intensity
Projection (Ave-IP) CT series were generated. During the treatment planning, the internal target volume (ITV) was outlined in
the MIP CT series. The PTV was created by adding a 5 mm margin from the ITV. In the same stage, the ﬁducial were marked in
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